About Tryton Medical
Tryton Medical is a developer of stent systems for the treatment of bifurcation lesions. The Tryton Side Branch Stent System is built for bifurcation using Tri-ZONE technology to offer a dedicated strategy for treating bifurcation lesions. Tryton's cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel. The stent system has received CE Mark and is commercially available throughout Europe, Russia and the Middle East. It is approved in the United States for investigational use only.
Missing: Tryton Medical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Tryton Medical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Tryton Medical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Tryton Medical is included in 2 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Tryton Medical Patents
Tryton Medical has filed 25 patents.
Implants (medicine), Prosthetics, Cardiology, Vascular diseases, Interventional cardiology
Implants (medicine), Prosthetics, Cardiology, Vascular diseases, Interventional cardiology
Latest Tryton Medical News
Nov 25, 2022
News Provided By Share This Article Bifurcation Lesions Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026 The Business Research Company’s Bifurcation Lesions Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026 LONDON, GREATER LONDON, UK, November 25, 2022 / EINPresswire.com / -- Avail a limited period discount of 33% on our uniquely designed Opportunities and Strategies market research reports. Contact us today and make winning strategies! As per The Business Research Company's " Bifurcation Lesions Global Market Report 2022 ”, the bifurcation lesions market is predicted to reach a value of $2.24 billion in 2022 at a compound annual growth rate (CAGR) of 5.59%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, effecting many markets across the globe. The bifurcation lesions market is expected to reach $2.97 billion in 2026 at a CAGR of 7.26%. The increasing geriatric population is expected to drive the growth of the bifurcation lesions market. Request a Sample now to gain a better understanding of bifurcation lesions market: Key Trends In The Bifurcation Lesions Market The advancement in devices used in imaging and procedures is a key trend that is gaining popularity in the bifurcation lesions market. Major companies operating in the market are concentrating their efforts on advancements in existing devices used in imaging and procedures. For instance, Advanced Bifurcation Systems (ABS), a clinical-stage medical device firm with a unique bifurcation stenting solution to standardize the treatment of all bifurcation lesions in coronary angioplasties, has a platform featuring the only modular self-aligning stent technology to evenly structure bifurcations. The ABS platform is a unique single system that reduces the need for repeat procedures and enables effective bifurcation stenting treatment. The bifurcation lesions consist of sales of bifurcation lesions by entities (organizations, sole traders, and partnerships) that refer to a coronary artery constriction that occurs next to or involves the origin of a vital side branch one does not want to lose. It occurs when plaque deposits accumulate, and the artery becomes too small for adequate blood flow to your heart. Learn more on the global bifurcation lesions market report at: Market Size Data • Forecast period: Historical and Future • By region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa. • By countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. Market Segmentation • By Application: Coronary Vascular, Peripheral Vascular • By Geography: The global bifurcation lesions market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America holds the largest share in the market. Major market players such as Boston Scientific Corporation, Terumo Medical Corporation, Spectranetics, Medtronic, Cardinal Health, Abbott, Tryton Medical Inc Trends, opportunities, strategies and so much more. Bifurcation Lesions Global Market Report 2022 is one of The Business Research Company’s comprehensive reports that provides in-depth bifurcation lesions global market research. The market report analyzes bifurcation lesions global market size, bifurcation lesions market growth drivers, bifurcation lesions market segments, bifurcation lesions global market major players, bifurcation lesions market growth across geographies, and bifurcation lesions global market competitors’ revenues and market positioning. The bifurcation lesions global market report enables you to gain insights on opportunities and strategies, as well as identify countries and segments with the highest growth potential. Not what you were looking for? Go through similar reports by The Business Research Company: Vascular Grafts Global Market Report 2022
Tryton Medical Frequently Asked Questions (FAQ)
When was Tryton Medical founded?
Tryton Medical was founded in 2003.
Where is Tryton Medical's headquarters?
Tryton Medical's headquarters is located at 1000 Park Forty Plaza, Durham.
What is Tryton Medical's latest funding round?
Tryton Medical's latest funding round is Series G.
How much did Tryton Medical raise?
Tryton Medical raised a total of $87M.
Who are the investors of Tryton Medical?
Investors of Tryton Medical include RiverVest Venture Partners, 3x5 Special Opportunity Partners, Evidity Health Capital, PTV Sciences, Spray Venture Partners and 4 more.
Who are Tryton Medical's competitors?
Competitors of Tryton Medical include Reva Medical, Svelte Medical Systems, Endologix, ArraVasc, IDev Technologies and 13 more.
Compare Tryton Medical to Competitors
Stent systems develops angioplasty catheters and guidewires, and related interventional products
SquareOne is developing a stent delivery system.
Svelte Medical Systems is engaged in the development of highly deliverable balloon expandable stents. The Svelte IDS is designed to realize the clinical, time and cost-savings benefits of direct stenting in a single platform. Svelte is developing a Sirolimus eluting stent that has non-inflammatory properties, potentially making it less irritating to the vessel lining than stents with typical polymeric coatings. The Svelte DES is being developed to have the same drug release kinetics as the market leaders while potentially minimizing inflammation in the vessel to reduce the need for long term dual anti-platelet therapy.
Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.
TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.
Micell Technologies aims to bring together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.